Drug news
Tarceva approved in EU as first line treatment against NSCLC with EGFR-mutations
Tarceva (erlotinib), an oral lung cancer treatment from Roche, has been officially licensed in the EU as first-line monotherapy for the treatment of patients with advanced forms of non-small cell lung cancer with EGFR-activating mutations.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.